Skip to main content
SpringerLink
Log in
Book cover

Veteran Psychiatry in the US pp 93–112Cite as

Treatment-Resistant Depression Among US Military Veterans

  • Chapter
  • First Online:

Abstract

Major depressive disorder is one of the most common behavioral disorders and with aggressive treatment roughly two-thirds of individuals will achieve remission. The remaining one-third comprise a group called treatment-resistant depression (TRD), characterized by significant residual symptoms, relapses, and a lowered quality of life. Helping individuals with TRD achieve remission requires a comprehensive, personalized approach. Military veterans with TRD have unique factors complicating recovery such as traumatic combat experiences. Other factors contributing to TRD include treatment adherence, co-occurring disorders, and inadequate medication trials. Best practice would include echelons of increasingly intensive treatments, measurement-based care, and consideration of newer pharmacologic strategies and nonpharmacologic interventions such as neuromodulation.

The views expressed in this article are those of the author and do not reflect the official policy of the Department of Army/Navy/Airforce, Department of Defense, or US Government

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®). 5th ed. Arlington: American Psychiatric Publishing; 2013.

    Book  Google Scholar 

  2. Quality. CfBHSa. 2015 National survey on drug use and health: detailed tables. Rockville: Substance Abuse and Mental Health Services Administration. p. 2016.

    Google Scholar 

  3. Gadermann AM, Engel CC, Naifeh JA, et al. Prevalence of DSM-IV major depression among U.S. military personnel: meta-analysis and simulation. Mil Med. 2012;177(8 0):47–59.

    Article  PubMed  Google Scholar 

  4. Blore JD, Sim MR, Forbes AB, Creamer MC, Kelsall HL. Depression in Gulf War veterans: a systematic review and meta-analysis. Psychol Med. 2015;45(8):1565–80.

    Article  CAS  PubMed  Google Scholar 

  5. Boakye EA, Buchanan P, Wang J, Stringer L, Geneus C, Scherrer JF. Self-reported lifetime depression and current mental distress among veterans across service eras. Mil Med. 2017;182(3–4):e1691–6.

    Article  PubMed  Google Scholar 

  6. Seal KH, Metzler TJ, Gima KS, Bertenthal D, Maguen S, Marmar CR. Trends and risk factors for mental health diagnoses among Iraq and Afghanistan veterans using Department of Veterans Affairs Health Care, 2002–2008. Am J Public Health. 2009;99(9):1651–8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Tanielian TL, Jaycox LH, editors. Invisible wounds of war: psychological and cognitive injuries, their consequences, and services to assist recovery. Santa Monica: RAND Corporation; 2008. https://www.rand.org/pubs/monographs/MG720.html. Also available in print form.

  8. Packnett ER, Elmasry H, Toolin CF, Cowan DN, Boivin MR. Epidemiology of major depressive disorder disability in the US military: FY 2007–2012. J Nerv Ment Dis. 2017;205(9):672–8.

    Article  PubMed  Google Scholar 

  9. Lande RG. Stress in service members. Psychiatr Clin. 2014;37(4):547–60.

    Google Scholar 

  10. Kelsey JE. Achieving remission in major depressive disorder: the first step to long-term recovery. J Am Osteopath Assoc. 2004;104(3 Suppl 1):S6–S10.

    PubMed  Google Scholar 

  11. Health NIoM. Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. 2017.

    Google Scholar 

  12. A. John Rush, Madhukar H. Trivedi, Stephen R. Wisniewski PD, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR * D report. Am J Psychiatr 2006;163(11):1905–1917.

    Google Scholar 

  13. Hales DJ, Rapaport MH, Moeller K. FOCUS Major depressive disorder maintenance of certification (MOC) workbook. American Psychiatric Publishing; 2012.

    Google Scholar 

  14. Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatric services (Washington, D.C.). 2014;65(8):977–87.

    Article  Google Scholar 

  15. Fekadu A, Wooderson SC, Markopoulo K, Donaldson C, Papadopoulos A, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116(1):4–11.

    Article  PubMed  Google Scholar 

  16. Cain RA. Navigating the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study: practical outcomes and implications for depression treatment in primary care. Prim Care. 2007;34(3):505–19, vi.

    Article  PubMed  Google Scholar 

  17. Trajkovic G, Starcevic V, Latas M, et al. Reliability of the Hamilton Rating Scale for Depression: a meta-analysis over a period of 49 years. Psychiatry Res. 2011;189(1):1–9.

    Article  PubMed  Google Scholar 

  18. Baer L, Blais MA. Handbook of clinical rating scales and assessment in psychiatry and mental health. New York: Humana Press; 2009.

    Google Scholar 

  19. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend. 2007;88(Suppl 2):S61–71.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Reilly TJ, MacGillivray SA, Reid IC, Cameron IM. Psychometric properties of the 16-item Quick Inventory of Depressive Symptomatology: a systematic review and meta-analysis. J Psychiatr Res. 2015;60:132–40.

    Article  PubMed  Google Scholar 

  21. Surís A, Holder N, Holliday R, Clem M. Psychometric validation of the 16 Item Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR16) in military veterans with PTSD. J Affect Disord. 2016;202(Supplement C):16–22.

    Article  PubMed  Google Scholar 

  22. Fowler JC, Patriquin M, Madan A, Allen JG, Frueh BC, Oldham JM. Early identification of treatment non-response utilizing the Patient Health Questionnaire (PHQ-9). J Psychiatr Res. 2015;68(Supplement C):114–9.

    Article  PubMed  Google Scholar 

  23. Kocalevent R-D, Hinz A, Brähler E. Standardization of the depression screener Patient Health Questionnaire (PHQ-9) in the general population. Gen Hosp Psychiatry. 2013;35(5):551–5.

    Article  PubMed  Google Scholar 

  24. Dunstan DA, Scott N, Todd AK. Screening for anxiety and depression: reassessing the utility of the Zung scales. BMC Psychiatry. 2017;17(1):329.

    Article  PubMed  PubMed Central  Google Scholar 

  25. O’Connor E, Rossom RC, Henninger M, et al. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Screening for Depression in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (US); 2016.

    Google Scholar 

  26. Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry. 2004;161(12):2163–77.

    Article  PubMed  Google Scholar 

  27. Association AP. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006: American Psychiatric Association; 2006.

    Google Scholar 

  28. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1–2):83–91.

    Article  CAS  PubMed  Google Scholar 

  29. Rytwinski NK, Scur MD, Feeny NC, Youngstrom EA. The co-occurrence of major depressive disorder among individuals with posttraumatic stress disorder: a meta-analysis. J Trauma Stress. 2013;26(3):299–309.

    Article  PubMed  Google Scholar 

  30. Elhai JD, Contractor AA, Tamburrino M, et al. Structural relations between DSM-5 PTSD and major depression symptoms in military soldiers. J Affect Disord. 2015;175(Supplement C):373–8.

    Article  PubMed  Google Scholar 

  31. Stander VA, Thomsen CJ, Highfill-McRoy RM. Etiology of depression comorbidity in combat-related PTSD: a review of the literature. Clin Psychol Rev. 2014;34(2):87–98.

    Article  PubMed  Google Scholar 

  32. Hepner KA, Sloss EM, Roth CP, et al. Quality of care for PTSD and depression in the military health system: phase I report. Rand Health Q. 2016;6(1):14.

    PubMed  PubMed Central  Google Scholar 

  33. Richardson JD, Contractor AA, Armour C, St Cyr K, Elhai JD, Sareen J. Predictors of long-term treatment outcome in combat and peacekeeping veterans with military-related PTSD. J Clin Psychiatry. 2014;75(11):e1299–305.

    Article  PubMed  Google Scholar 

  34. Ramsawh HJ, Fullerton CS, Mash HBH, et al. Risk for suicidal behaviors associated with PTSD, depression, and their comorbidity in the U.S. Army. J Affect Disord. 2014;161(Supplement C):116–22.

    Article  PubMed  Google Scholar 

  35. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. Br J Psychiatry J Ment Sci. 2006;188:13–20.

    Article  Google Scholar 

  36. Skodol AE, Grilo CM, Keyes KM, Geier T, Grant BF, Hasin DS. Relationship of personality disorders to the course of major depressive disorder in a nationally representative sample. Am J Psychiatry. 2011;168(3):257–64.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Fisher LB, Fava M, Doros GD, et al. The role of anger/hostility in treatment-resistant depression: a secondary analysis from the ADAPT-A study. J Nerv Ment Dis. 2015;203(10):762–8.

    Article  PubMed  Google Scholar 

  38. Dutton DG, Karakanta C. Depression as a risk marker for aggression: a critical review. Aggress Violent Behav. 2013;18(2):310–9.

    Article  Google Scholar 

  39. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):18–25.

    CAS  PubMed  Google Scholar 

  40. Lan C-W, Fiellin DA, Barry DT, et al. The epidemiology of substance use disorders in US Veterans: a systematic review and analysis of assessment methods. Am J Addict. 2016;25(1):7–24.

    Article  PubMed  Google Scholar 

  41. Fuehrlein BS, Mota N, Arias AJ, et al. The burden of alcohol use disorders in US military veterans: results from the National Health and Resilience in Veterans Study. Addiction. 2016;111(10):1786–94.

    Article  PubMed  Google Scholar 

  42. Lande RG, Marin BA, Chang AS, Lande GR. Survey of alcohol use in the U.S. army. J Addict Dis. 2008;27(3):115–21.

    Article  PubMed  Google Scholar 

  43. Thomas KH, Turner LW, Kaufman EM, et al. Predictors of depression diagnoses and symptoms in Veterans: results from a national survey. Mil Behav Health. 2015;3(4):255–65.

    Article  Google Scholar 

  44. Hawton K, Casañas i Comabella C, Haw C, Saunders K. Risk factors for suicide in individuals with depression: a systematic review. J Affect Disord. 2013;147(1):17–28.

    Article  PubMed  Google Scholar 

  45. Kimbrel NA, Newins AR, Dedert EA, et al. Cannabis use disorder and suicide attempts in Iraq/Afghanistan-era veterans. J Psychiatr Res. 2017;89(Supplement C):1–5.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Scherrer JF, Salas J, Sullivan MD, et al. The influence of prescription opioid use duration and dose on development of treatment resistant depression. Prev Med. 2016;91:110–6.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Scherrer JF, Salas J, Copeland LA, et al. Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. Ann Fam Med. 2016;14(1):54–62.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Prochaska JJ, Das S, Young-Wolff KC. Smoking, mental illness, and public health. Annu Rev Public Health. 2017;38:165–85.

    Article  PubMed  Google Scholar 

  49. Weinberger AH, Kashan RS, Shpigel DM, et al. Depression and cigarette smoking behavior: a critical review of population-based studies. Am J Drug Alcohol Abuse. 2017;43(4):416–31.

    Article  PubMed  Google Scholar 

  50. Paul K, Erin R, David S, Steven F, Binhuan W, Scott S. Relationship between tobacco cessation and mental health outcomes in a tobacco cessation trial. J Health Psychol. 2016. https://doi.org/10.1177/1359105316644974.

  51. Kahler CW, Spillane NS, Busch AM, Leventhal AM. Time-varying smoking abstinence predicts lower depressive symptoms following smoking cessation treatment. Nicotine Tob Res. 2011;13(2):146–50.

    Article  PubMed  Google Scholar 

  52. Morozova M, Rabin RA, George TP. Co-morbid tobacco use disorder and depression: a re-evaluation of smoking cessation therapy in depressed smokers. Am J Addict. 2015;24(8):687–94.

    Article  PubMed  Google Scholar 

  53. Secades-Villa R, Gonzalez-Roz A, Garcia-Perez A, Becona E. Psychological, pharmacological, and combined smoking cessation interventions for smokers with current depression: a systematic review and meta-analysis. PLoS One. 2017;12(12):e0188849.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Correa R, Akiskal H, Gilmer W, Nierenberg AA, Trivedi M, Zisook S. Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? J Affect Disord. 2010;127(1–3):10–8.

    Article  CAS  PubMed  Google Scholar 

  55. Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–70.

    Article  PubMed  Google Scholar 

  56. Lopresti AL, Hood SD, Drummond PD. A review of lifestyle factors that contribute to important pathways associated with major depression: diet, sleep and exercise. J Affect Disord. 2013;148(1):12–27.

    Article  PubMed  Google Scholar 

  57. Iosifescu DV, Bankier B, Fava M. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr Psychiatry Rep. 2004;6(3):193–201.

    Article  PubMed  Google Scholar 

  58. Gupta MA, Simpson FC. Obstructive sleep apnea and psychiatric disorders: a systematic review. J Clin Sleep Med. 2015;11(2):165–75.

    PubMed  PubMed Central  Google Scholar 

  59. McLay RN, Klam WP, Volkert SL. Insomnia is the most commonly reported symptom and predicts other symptoms of post-traumatic stress disorder in US service members returning from military deployments. Mil Med. 2010;175(10):759.

    Article  PubMed  Google Scholar 

  60. Lande RG. Sleep problems, posttraumatic stress, and mood disorders among active-duty service members. J Am Osteopath Assoc. 2014;114(2):83–9.

    Article  PubMed  Google Scholar 

  61. Lande RG, Gragnani CT, Pourzand M, Hangemanole D. Alcohol biomarkers associated with obstructive sleep apnea. Subst Use Misuse. 2018;53(5):867–72.

    Google Scholar 

  62. Lande RG, Gragnani CT. Tobacco use & sleep problems among active duty service members. Osteopath Fam Phys. 2017;9(4):10.

    Google Scholar 

  63. Moyer CA, Sonnad SS, Garetz SL, Helman JI, Chervin RD. Quality of life in obstructive sleep apnea: a systematic review of the literature. Sleep Med. 2001;2(6):477–91.

    Article  CAS  PubMed  Google Scholar 

  64. Edwards C, Mukherjee S, Simpson L, Palmer LJ, Almeida OP, Hillman DR. Depressive symptoms before and after treatment of obstructive sleep apnea in men and women. J Clin Sleep Med. 2015;11(9):1029–38.

    PubMed  PubMed Central  Google Scholar 

  65. Orr JE, Smales C, Alexander TH, et al. Treatment of OSA with CPAP is associated with improvement in PTSD symptoms among veterans. J Clin Sleep Med. 2017;13(1):57–63.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Krystal AD. Psychiatric disorders and sleep. Neurol Clin. 2012;30(4):1389–413.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Iosifescu DV, Nierenberg AA, Alpert JE, et al. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatr. 2003;160(12):2122–7.

    Article  PubMed  Google Scholar 

  68. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163(20):2433–45.

    Article  PubMed  Google Scholar 

  69. Cosci F, Fava GA, Sonino N. Mood and anxiety disorders as early manifestations of medical illness: a systematic review. Psychother Psychosom. 2015;84(1):22–9.

    Article  PubMed  Google Scholar 

  70. Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: a clinical review. Eur Heart J. 2014;35(21):1365–72.

    Article  PubMed  Google Scholar 

  71. Cherbuin N, Kim S, Anstey KJ. Dementia risk estimates associated with measures of depression: a systematic review and meta-analysis. BMJ Open. 2015;5(12):e008853.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Snowden MB, Atkins DC, Steinman LE, et al. Longitudinal association of dementia and depression. Am J Geriatr Psychiatry. 2015;23(9):897–905.

    Article  PubMed  Google Scholar 

  73. Morimoto SS, Kanellopoulos D, Manning KJ, Alexopoulos GS. Diagnosis and treatment of depression and cognitive impairment in late life. Ann N Y Acad Sci. 2015;1345(1):36–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet (London, England). 2003;361(9358):653–61.

    Article  CAS  Google Scholar 

  75. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999;60(Suppl 22):29–34.

    PubMed  Google Scholar 

  76. Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci. 2012;9(5–6):41–6.

    PubMed  PubMed Central  Google Scholar 

  77. Mandrioli R, Mercolini L, Saracino MA, Raggi MA. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem. 2012;19(12):1846–63.

    Article  CAS  PubMed  Google Scholar 

  78. Caley CF, Kando JC. SSRI efficacy—finding the right dose. J Psychiatr Pract. 2002;8(1):33–40.

    Article  PubMed  Google Scholar 

  79. Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH. Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatr. 2015;173(2):174–83.

    Article  PubMed  Google Scholar 

  80. Safer DJ. Raising the minimum effective dose of serotonin reuptake inhibitor antidepressants: adverse drug events. J Clin Psychopharmacol. 2016;36(5):483–91.

    Article  CAS  PubMed  Google Scholar 

  81. Rush AJ. STAR* D: what have we learned? Am J Psychiatr. 2007;164(2):201–4.

    Article  PubMed  Google Scholar 

  82. Uher R, Mors O, Rietschel M, et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Clin Psychiatry. 2011;72(11):1478–84.

    Article  PubMed  Google Scholar 

  83. Group MoMW. VA/DoD clinical practice guideline for management of major depressive disorder (MDD). Washington, DC: Department of Defense and Department of Veterans Affairs; 2009.

    Google Scholar 

  84. Hepner KA, Farris C, Farmer CM, et al. Delivering clinical practice guideline-concordant care for Ptsd and major depression in military treatment facilities. Santa Monica: RAND Corporation; 2017.

    Book  Google Scholar 

  85. O’Donohue W, Draper C. Stepped care and e-Health: practical applications to behavioral disorders. New York: Springer New York; 2010.

    Google Scholar 

  86. Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr. 2007;12(8 Suppl 13):1–27.

    PubMed  Google Scholar 

  87. Health NCCfM. Depression: the treatment and management of depression in adults (updated edition). 2010.

    Google Scholar 

  88. van Straten A, Hill J, Richards DA, Cuijpers P. Stepped care treatment delivery for depression: a systematic review and meta-analysis. Psychol Med. 2014;45(2):231–46.

    Article  PubMed  Google Scholar 

  89. Firth N, Barkham M, Kellett S. The clinical effectiveness of stepped care systems for depression in working age adults: a systematic review. J Affect Disord. 2015;170:119–30.

    Article  PubMed  Google Scholar 

  90. Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines: impact on depression in primary care. JAMA. 1995;273(13):1026–31.

    Article  CAS  PubMed  Google Scholar 

  91. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. The Cochrane Library. 2009.

    Google Scholar 

  92. Cipriani A, Purgato M, Furukawa TA, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012;(7):Cd006534.

    Google Scholar 

  93. de Silva VA, Hanwella R. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies. Int Clin Psychopharmacol. 2012;27(1):8–16.

    Article  PubMed  Google Scholar 

  94. Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiat. 2017;74(1):9–10.

    Article  Google Scholar 

  95. Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. The Cochrane Library. 2010.

    Google Scholar 

  96. Rocha FL, Fuzikawa C, Riera R, Hara C. Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol. 2012;32(2):278–81.

    Article  CAS  PubMed  Google Scholar 

  97. Mohamed S, Johnson GR, Vertrees JE, et al. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: rationale and design considerations. Psychiatry Res. 2015;229(3):760–70.

    Article  PubMed  Google Scholar 

  98. Mohamed S, Johnson GR, Chen P, et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA. 2017;318(2):132–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Fava M. Lessons learned from the VA augmentation and switching treatments for improving depression outcomes (VAST-D) study. JAMA. 2017;318(2):126–8.

    Article  PubMed  Google Scholar 

  100. Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord. 2014;168:269–75.

    Article  CAS  PubMed  Google Scholar 

  101. Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs. 2014;28(4):331–42.

    Article  CAS  PubMed  Google Scholar 

  102. Abraham G, Milev R, Lawson JS. T3 augmentation of SSRI resistant depression. J Affect Disord. 2006;91(2):211–5.

    Article  CAS  PubMed  Google Scholar 

  103. Aronson R, Offman HJ, Joffe RT, Naylor C. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry. 1996;53(9):842–8.

    Article  CAS  PubMed  Google Scholar 

  104. Morin AK. Triiodothyronine (T3) supplementation in major depressive disorder. Ment Health Clin. 2015;5(6):253–9.

    Article  Google Scholar 

  105. Ricken R, Ulrich S, Schlattmann P, Adli M. Tranylcypromine in mind (Part II): review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol. 2017;27(8):714–31.

    Article  CAS  PubMed  Google Scholar 

  106. Linde K, Kriston L, Rücker G, et al. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann Fam Med. 2015;13(1):69–79.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Undurraga J, Baldessarini RJ. Direct comparison of tricyclic and serotonin-reuptake inhibitor antidepressants in randomized head-to-head trials in acute major depression: systematic review and meta-analysis. J Psychopharmacol. 2017. https://doi.org/10.1177/0269881117711709.

  108. Shinohara K, Honyashiki M, Imai H, et al. Behavioural therapies versus other psychological therapies for depression. The Cochrane Library. 2013.

    Google Scholar 

  109. Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006;26(1):17–31.

    Article  PubMed  Google Scholar 

  110. Abbass AA. Intensive Short-Term Dynamic Psychotherapy of treatment-resistant depression: a pilot study. Depress Anxiety. 2006;23(7):449–52.

    Article  PubMed  Google Scholar 

  111. Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet. 2013;381(9864):375–84.

    Article  PubMed  Google Scholar 

  112. Souza LH, Salum GA, Mosqueiro BP, Caldieraro MA, Guerra TA, Fleck MP. Interpersonal psychotherapy as add-on for treatment-resistant depression: a pragmatic randomized controlled trial. J Affect Disord. 2016;193:373–80.

    Article  PubMed  Google Scholar 

  113. Holtzheimer PE, Mayberg HS. Neuromodulation for treatment-resistant depression. F1000 Med Rep. 2012;4:22.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Holtzheimer PE, McDonald W. A clinical guide to transcranial magnetic stimulation. New York: Oxford University Press; 2014.

    Book  Google Scholar 

  115. Janicak PG, Dokucu ME. Transcranial magnetic stimulation for the treatment of major depression. Neuropsychiatr Dis Treat. 2015;11:1549–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Conelea CA, Philip NS, Yip AG, et al. Transcranial magnetic stimulation for treatment-resistant depression: naturalistic treatment outcomes for younger versus older patients. J Affect Disord. 2017;217:42–7.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Kozel FA, Hernandez M, Van Trees K, et al. Clinical repetitive transcranial magnetic stimulation for veterans with major depressive disorder. Ann Clin Psychiatry. 2017;29(4):242–8.

    PubMed  Google Scholar 

  118. Lande RG, Pierce J. Efficacy of transcranial magnetic stimulation for treatment resistant depression among active duty service members. Gen Hosp Psychiatry. 2017;45:99–100.

    Article  PubMed  Google Scholar 

  119. Leggett LE, Soril LJJ, Coward S, Lorenzetti DL, MacKean G, Clement FM. Repetitive transcranial magnetic stimulation for treatment-resistant depression in adult and youth populations: a systematic literature review and meta-analysis. Primary Care Companion CNS Disord. 2015;17(6) https://doi.org/10.4088/PCC.4015r01807.

  120. McClintock SM, Reti IM, Carpenter LL, McDonald WM, Dubin M, Taylor SF, Cook IA, O’Reardon J, Husain MM, Wall C, Krystal AD, Sampson SM, Morales O, Nelson BG, Latoussakis V, George MS, Lisanby SH, National Network of Depression Centers rTMS Task Group, American Psychiatric Association Council on Research Task Force on Novel Biomarkers and Treatments. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry. 2018;79(1). pii: 16cs10905. https://doi.org/10.4088/JCP.16cs10905.

  121. Chen J-j, Zhao L-b, Liu Y-y, Fan S-h, Xie P. Comparative efficacy and acceptability of electroconvulsive therapy versus repetitive transcranial magnetic stimulation for major depression: a systematic review and multiple-treatments meta-analysis. Behav Brain Res. 2017;320:30–6.

    Article  PubMed  Google Scholar 

  122. Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015;(9):Cd011612.

    Google Scholar 

  123. Vigo DV, Baldessarini RJ. Anticonvulsants in the treatment of major depressive disorder: an overview. Harv Rev Psychiatry. 2009;17(4):231–41.

    Article  PubMed  Google Scholar 

  124. Shariq AS, Brietzke E, Rosenblat JD, Barendra V, Pan Z, McIntyre RS. Targeting cytokines in reduction of depressive symptoms: a comprehensive review. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;83:86–91.

    Article  CAS  Google Scholar 

  125. Wohleb ES, Franklin T, Iwata M, Duman RS. Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci. 2016;17(8):497–511.

    Article  CAS  PubMed  Google Scholar 

  126. Smith KJ, Au B, Ollis L, Schmitz N. The association between C-reactive protein, Interleukin-6 and depression among older adults in the community: a systematic review and meta-analysis. Exp Gerontol. 2018;102:109–32.

    Article  CAS  PubMed  Google Scholar 

  127. Köhler O, Krogh J, Mors O, Benros ME. Inflammation in depression and the potential for anti-inflammatory treatment. Curr Neuropharmacol. 2016;14(7):732–42.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Harbottle L, Schonfelder N. Nutrition and depression: a review of the evidence. J Ment Health. 2008;17(6):576–87.

    Article  Google Scholar 

  129. Taylor MJ, Carney SM, Geddes J, Goodwin G. Folate for depressive disorders. The Cochrane Library. 2003.

    Google Scholar 

  130. Shaffer JA, Edmondson D, Wasson LT, et al. Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials. Psychosom Med. 2014;76(3):190.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Register OotF. Code of Federal Regulations, Title 38, Pensions, Bonuses, and Veterans’ Relief, Pt. 0–17, Revised as of July 1 2010. U.S. Government Printing Office; 2010.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatry Continuity Service, Walter Reed National Military Medical Center, Behavioral Health, Bethesda, MD, USA

    R. Gregory Lande

Authors
  1. R. Gregory Lande
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Gregory Lande .

Editor information

Editors and Affiliations

  1. Mental Health Community Based Outpatient, Georgetown University, Mental Health Community Based Outpatient, Silver Spring, MD, USA

    Elspeth Cameron Ritchie

  2. Georgetown University School of Medicine, Washington DC VA Medical Center, Department of Psychiatry, Washington, DC, USA

    Maria D. Llorente

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lande, R.G. (2019). Treatment-Resistant Depression Among US Military Veterans. In: Ritchie, E., Llorente, M. (eds) Veteran Psychiatry in the US. Springer, Cham. https://doi.org/10.1007/978-3-030-05384-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-05384-0_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-05383-3

  • Online ISBN: 978-3-030-05384-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation